James V. Caruso - Jun 14, 2024 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Role
President and CEO, Director
Signature
/s/ Christina Blakley, attorney-in-fact for James V. Caruso
Stock symbol
CLRB
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 05:04 PM
Previous filing
Dec 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLRB Stock option (right to buy) Award $0 +900K $0.00 900K Jun 14, 2024 Common Stock 900K $2.65 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024.
F2 This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023.